OBJECTIVE: To determine whether Smurf2, an E3 ubiquitin ligase known to inhibit transforming growth factor beta (TGFbeta) signaling, is expressed in human osteoarthritic (OA) cartilage and can initiate OA in mice. METHODS: Human OA cartilage was obtained from patients undergoing knee arthroplasty. Samples were graded histologically using the Mankin scale and were examined immunohistochemically for Smurf2 expression. A transgene driven by the collagen 2alpha1 promoter was used to overexpress Smurf2 in mice. Smurf2 overexpression in mouse sternal chondrocytes was confirmed by reverse transcription-polymerase chain reaction and Western blotting. Changes in articular cartilage area, chondrocyte number, and chondrocyte diameter were assessed histomorphometrically using OsteoMeasure software. Alterations in type X collagen and matrix metalloproteinase 13 (MMP-13) in articular chondrocytes were examined by in situ hybridization and immunohistochemistry, respectively. Joint bone phenotypes were evaluated by microfocal computed tomography. The effects of Smurf2 overexpression on TGFbeta signaling were examined using a luciferase-based reporter and immunoprecipitation/Western blotting. RESULTS: Human OA cartilage strongly expressed Smurf2 as compared with nonarthritic human cartilage. By 8 months of age, Smurf2-transgenic mice exhibited decreased articular cartilage area, fibrillation, clefting, eburnation, subchondral sclerosis, and osteophytes. Increased expression of type X collagen and MMP-13 were also detected in articular cartilage from transgenic mice. Transgenic sternal chondrocytes showed reduced TGFbeta signaling as well as decreased expression and increased ubiquitination of pSmad3. CONCLUSION: Smurf2 is up-regulated during OA in humans, and Smurf2-transgenic mice spontaneously develop an OA-like phenotype that correlates with decreased TGFbeta signaling and increased pSmad3 degradation. Overall, these results suggest a role of Smurf2 in the pathogenesis of OA.
OBJECTIVE: To determine whether Smurf2, an E3 ubiquitin ligase known to inhibit transforming growth factor beta (TGFbeta) signaling, is expressed in humanosteoarthritic (OA) cartilage and can initiate OA in mice. METHODS:Human OA cartilage was obtained from patients undergoing knee arthroplasty. Samples were graded histologically using the Mankin scale and were examined immunohistochemically for Smurf2 expression. A transgene driven by the collagen 2alpha1 promoter was used to overexpress Smurf2 in mice. Smurf2 overexpression in mouse sternal chondrocytes was confirmed by reverse transcription-polymerase chain reaction and Western blotting. Changes in articular cartilage area, chondrocyte number, and chondrocyte diameter were assessed histomorphometrically using OsteoMeasure software. Alterations in type X collagen and matrix metalloproteinase 13 (MMP-13) in articular chondrocytes were examined by in situ hybridization and immunohistochemistry, respectively. Joint bone phenotypes were evaluated by microfocal computed tomography. The effects of Smurf2 overexpression on TGFbeta signaling were examined using a luciferase-based reporter and immunoprecipitation/Western blotting. RESULTS:Human OA cartilage strongly expressed Smurf2 as compared with nonarthritic humancartilage. By 8 months of age, Smurf2-transgenic mice exhibited decreased articular cartilage area, fibrillation, clefting, eburnation, subchondral sclerosis, and osteophytes. Increased expression of type X collagen and MMP-13 were also detected in articular cartilage from transgenic mice. Transgenic sternal chondrocytes showed reduced TGFbeta signaling as well as decreased expression and increased ubiquitination of pSmad3. CONCLUSION:Smurf2 is up-regulated during OA in humans, and Smurf2-transgenic mice spontaneously develop an OA-like phenotype that correlates with decreased TGFbeta signaling and increased pSmad3 degradation. Overall, these results suggest a role of Smurf2 in the pathogenesis of OA.
Authors: Sonya S Glasson; Roger Askew; Barbara Sheppard; Brenda A Carito; Tracey Blanchet; Hak-Ling Ma; Carl R Flannery; Kim Kanki; Eunice Wang; Diane Peluso; Zhiyong Yang; Manas K Majumdar; Elisabeth A Morris Journal: Arthritis Rheum Date: 2004-08
Authors: Lara Kevorkian; David A Young; Clare Darrah; Simon T Donell; Lee Shepstone; Sarah Porter; Sarah M V Brockbank; Dylan R Edwards; Andrew E Parker; Ian M Clark Journal: Arthritis Rheum Date: 2004-01
Authors: Erik R Sampson; Matthew J Hilton; Ye Tian; Di Chen; Edward M Schwarz; Robert A Mooney; Susan V Bukata; Regis J O'Keefe; Hani Awad; J Edward Puzas; Randy N Rosier; Michael J Zuscik Journal: Sci Transl Med Date: 2011-09-21 Impact factor: 17.956
Authors: Jiang Liying; Tao Yuchun; Wang Youcheng; Wang Yingchen; Jin Chunyu; Yin Yanling; Jin Hongmei; Li Yujie Journal: Rheumatol Int Date: 2013-01-06 Impact factor: 2.631
Authors: Jixiang Shi; Qianqian Liang; Michael Zuscik; Jie Shen; Di Chen; Hao Xu; Yong-Jun Wang; Yan Chen; Ronald W Wood; Jia Li; Brendan F Boyce; Lianping Xing Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995
Authors: Tracey E Swingler; Jasmine G Waters; Rosemary K Davidson; Caroline J Pennington; Xose S Puente; Clare Darrah; Adele Cooper; Simon T Donell; Geoffrey R Guile; Wenjia Wang; Ian M Clark Journal: Arthritis Res Ther Date: 2009-06-23 Impact factor: 5.156